Prävention intrakardialer Thromben und systemischer Embolien nach Herzklappenersatz

D. Horstkotte

doi:10.1055/s-0038-1655233

Hämostaseologie, Inhaltsverzeichnis

Hamostaseologie 1993; 13(04): 172-180
DOI: 10.1055/s-0038-1655233

Übersichtsarbeiten/Review Articles

Schattauer GmbH

Prävention intrakardialer Thromben und systemischer Embolien nach Herzklappenersatz

Gesicherte Erkenntnisse und zukünftige Entwicklungen

D. Horstkotte

¹Abteilung für Kardiologie, Pneumologie und Angiologie der Medizinischen Klinik und Poliklinik, Heinrich-Heine-Universität Düsseldorf (Direktor: Prof. Dr. B. E. Strauer)

› Institutsangaben

Abstract

Zusammenfassung

Obwohl bislang keine prospektiven Dosisfindungsstudien durchgeführt wurden, wird für Patienten mit mechanischen Herzklappenprothesen eine orale Dauerantikoagulation mit einer Intensität von INR 3,0-4,5 empfohlen. Jüngste Untersuchungen zum optimalen Management einer oralen Antikoagulation bei Kunstklappenträgern belegen (a) die Unzulänglichkeit der Therapiesteuerung mittels des Quick-Wertes, (b) Unterschiede in der Thrombogenität älterer wie auch der heute verfügbaren Prothesen, (c) die Notwendigkeit einer individuellen Antikoagulation aufgrund der patientenseitigen Koagulabilität, (d) die Berücksichtigung der unabhängig von der implantierten Prothese zu intrakardialen Thrombosen und konsekutiven Embolien prädisponierenden kardialen Morphologie und Physiologie.

Schlüsselwörter

Orale Antikoagulation - Herzklappenprothesen - Thrombogenität - Thrombembolien - Antikoagulation - INR - Kardioembolien - St.-Jude-Medical-Prothese

Volltext

Referenzen

LITERATUR
1 Horstkotte D. Abnormal cardiac anatomy and physiology. In: Thrombosis, Embolism and Bleeding. Butchart EG, Bodnar E. (eds). London: ICR Publishers; 1992: 31-69.
2 Edmunds LH. Thromboembolic complications of current cardiac valvular prostheses. Ann Thorac Sur 1981; 34: 96.
3 Anderson JM, Schoen EJ. Interactions of blood with artificial surfaces. In: Thrombosis, Embolism and Bleeding. Butchart E, Bodnar E. (eds). London: ICR Publishers; 1992: 160-71.
4 Horstkotte D, Aul C, Seipel L, Körfer R, Budde TH, Schulte HD, Bircks W, Loogen F. Einfluß von Klappentyp und Klappenfunktion auf die chronische intravasale Hämolyse nach alloprothetischem Mitral- und Aortenklappenersatz. Z Kardiol 1983; 72: 119-31.
5 Steele P, Weity H, Davies H, Pappas G, Genton E. Platelet survival time following aortic valve replacement. Circulation 1975; 51: 358.
6 Petschek ME, Adamis D, Kantrowitz AR. Stagnation flow thrombus formation. Trans Am Soc Intern Organs 1968; 14: 256.
7 Blackstone EH, Kirklin JW. Death and other time-related events after valve replacement. Circulation 1985; 72: 753-67.
8 Horstkotte D, Schulte HD, Bircks W, Loogen F. The hazard of thrombembolism with chronic mitral lesions before and after valve replacement. Eur Heart J 1987; 08 (Suppl. 02) 443.
9 Horstkotte D, Schulte HD, Bircks W, Strauer BE. Unexpected findings concerning thromboembolic complications and anticoagulation after complete ten-year follow- up of patients with St. Jude Medical prostheses. J Heart Valve Dis 1993; 02: 291-301.
10 Myers ML, Lawrie GM, Crawford ESt, Howell JF, Morris GC, Glaeser DH, DeBakey ME. The St. Jude valve prosthesis: Analysis of the clinical results in 815 implants and the need for systemic anticoagulation. JACC 1989; 13: 57-62.
11 Baudet EM, Oca CC, Roques XF, Laborde MN, Hafez AS, Collot MA, Ghidom IM. A 5V2-year experience with the St. Jude Medical cardiac valve prosthesis. J Thorac Cardiovasc Surg 1985; 90: 137-44.
12 Mok CK, Boey J, Wang R, Chan TK, Cheung KL, Lee PK, Chow J, Ng PR, Tse TF. Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial. Circulation 1985; 72: 1059-63.
13 Cook DJ, Guyatt GH, Laupacis A, Sackett DL. Rules of evidence and clinical recommendation on the use of antithrombotic agents. Chest 1992; 102 (Suppl): 305-11.
14 Dalen JE, Hirsh J. Am College of Chest Physicians and the National Heart, Lung and Blood Institute National Converence on Antithrombotic Therapy. Arch Int Med 1980; 146: 462-72.
15 Hirsh J, Poller L, Deykin D, Levine M, Dalen JE. Optimal therapeutic range for oral anticoagulants. Chest 1989; 95 (Suppl): 5-11.
16 bBritish Society of Haematology, British Committee for Standards in Haematology, Haemostasis and Thrombosis Task Force. Guidelines on oral anticoagulation: second edition. J Clin Pathol 1990; 43: 177-83.
17 Loeliger EA. Therapeutic target values in oral anticoagulation. Justification of Dutch policy and a warning against so-called moderate-intensity regimes. Ann Hematol 1992; 64: 60-5.
18 Horstkotte D, Bodnar E. Bileaflet prostheses. In: Replacement Cardiac Valves. Bodnar E, Frater RWM. (eds). New York: Pergamon; 1991: 201-28.
19 Butchart EG. Prosthesis-specific and patient-specific anticoagulation. In: Thrombosis, Embolism and Bleeding. Butchart EG, Bodnar E. (eds). London: ICR Publishers; 1991: 293-317.
20 Harker LA, Slichter SJ. Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves. N Engl J Med 1970; 283: 1302-5.
21 Meade TW, Vickers MV, Thompson SG, Seghatchian MJ. The effect of physiological levels of fibrinogen on platelet aggregation. Thromb Res 1985; 38: 527-34.
22 Pengo V, Peruzzi P, Baca M, Marzari A, Zanon F, Schivapappa L, Dalla A. The optimal therapeutic range for oral anticoagulant treatment as suggested by fibronopeptide A levels in patients with heart valve prostheses. Eur J Clin Invest 1989; 19: 181-4.
23 Bruhn HD, Zurborn KH. Messung des Prothrombinfragments F₁₊₂ zur Kontrolle der antikoagulatorischen Wirkung von Phenprocoumon. Dtsch Med Wochensch 1993; 118: 967-70.
24 Saour JN, Sieck JO, Mamo LA, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990; 322: 428-32.
25 Altman R, Rouvier J, Gurfinkel E, D’Ortencio I, Manzanel R, de la Fuente L, Favaloro RG. Comparison of two levels of anticoagulant therapy in patients with prosthetic heart valves. J Thorac Cardiovasc Surg 1991; 101: 427-31.
26 Turpie AGG, Gustensen J, Hirsh J, Nelson H, Gent M. Randomised comparison of two intensities of oral anticoagulant therapy after tissue valve replacement. Lancet 1988; 01: 1242-5.
27 Butchart EG, Lewis PA, Bethel PA, Bekkenridge IM. Adjusting anticoagulation to prosthesis thrombogenicity and patient risk factors: recommendations for the Medtronic-Hall valve. Circulation. 1991; 84 (Suppl. III): 61-9.
28 Horstkotte D, Bergemann R, Althaus U. et al. German experience with low intensity anticoagulation (GELIA): Protocol of a multicenter randomized prospective study with the St. Jude Medical valve. J Heart Valve Dis 1993; 02: 409-19.
29 Der Arzneimittelbrief. Antikoagulation and Thrombozytenaggregation in der Kardiologie. 1991; 12-91.
30 Gohlke-Bärwolf C, Acar J, Burckhardt D, Oakley C, Butchart E, Krayenbühl P, Hall R, Bodnar E, Krzeminska-Pakula M, Delahaye JP, Samama M. b(Ad Hoc Committee of the Working Group on Valvular Heart Disease, European Society of Cardiology. Guidelines for prevention of thromboembolic events in valvular heart disease. J Heart Valve Dis 1993; 02: 398-410.
31 Acar J. Thromboembolic events in prosthetic valve recipients : What is the safe level of anticoagulation?. J Heart Valve Dis 1993; 02: 395-7.
32 Butchart EG, Lewis PA, Grunkemeier GL, Kulatilake N, Beckenridge IM. Low risk of thrombosis and serious embolic events despite low intensity anticoagulation. Circulation 1988; 78 (Suppl I): 166-177.
33 Quick AJ. The prothrombin time in haemophilia and in obstructive jaundice. J Biol Chem 1935; 109: 73-4.
34 van den Besselaar AMH, van der Meer FJM. Standardisation of oral anticoagulation measurement and management. In: Thrombosis, Embolism and Bleeding. Butchart EG, Bodnar E. (eds). London: ICR Publishers; 1992: 277-92.
35 Bodnar E, Horstkotte D. Potential flaws in the assessment of minor cerebrovascular events after heart valve replacement. J Heart Valve Dis 1993; 02: 287-90.
36 Aris A, Padro JM, Camara ML, Crexells C, Auge JM, Caralps JM. Clinical and hemodynamic results of cardiac valve replacement with the Monostrut Björk-Shiley prosthesis. J Thorac Cardiovasc Surg 1988; 95: 423-31.
37 Castillon C. Five years experience with the Björk-Shiley Monostrut valve in 2726 patients: a Spanish multicentre study. In: Surgery for Heart Valve Disease. Bodnar E. (ed). London: ICR Publishers; 1990: 268-85.
38 Lindblom D, Lindblom V, Henze A, Bjork VO, Semb BK. Three-year clinical results with the Monostrut Björk-Shiley prosthesis. J Thorac Cardiovasc Surg 1987; 94: 34-43.
39 Nakano S, Kawashima Y, Matsuda H, Sakai K, Taniguchi K, Kawamoto T. A five-year appraisal and hemodynamic evaluation of the Björk-Shiley Monostrut valve. J Thorac Cardiovasc Surg 1991; 101: 881-7.
40 Nashef SAM. An evaluation of the Björk-Shiley Monostrut valve. Monostrut Valve Symposium. Dallas: Texas; 1987
41 Peterfly A, Bekassy SM, Voith L. Clinical experience with the Björk-Shiley integral Monostrut heart valve prosthesis in the aortic and mitral position. J Cardiovasc Surg 1987; 28: 642-5.
42 Horstkotte D. Heart Valve Consultant. London: ICR Publishers; 1991
43 Cortina JM, Martinell J, Artitz V. Comparative clinical results with Omniscience, Medtronic Hall, and Björk-Shiley Convexo-Concave (70°) prostheses in mitral valve replacement. J Thorac Cardiovasc Surg 1986; 91: 174-83.
44 Keenan B. Clinical experience with the Medtronic Hall prosthesis. ATS 1990; 50: 748-53.
45 Nitter-Hauge S. Ten-year experience with the Medtronic Hall valvular prosthesis. A study of 1104 patients. Circulation 1989; 80 (Suppl I): 143-148.
46 Vallejo JL, Gonzalez-Santos JM, Albertos J. Eight years experience with the Medtronic Hall valve prosthesis. ATS 1990; 50: 429-36.
47 Beaudet RL, Poirier NL, Dovle D. The Medtronic Hall cardiac valve: 71/2 years clinical experience. Ann Thorac Surg 1986; 42: 644-50.
48 Bhatnagar NK, Hutter JA, Dhasmana JP, Wisheart JD, Jackson M, Keen G. CarboMedics valve - the Bristol experience. Third International Clinical Symposium 1991; 89-95.
49 CarboMedics. Summary of clinical investigation. Clinical Report. 1992 04. No. 1.
50 LeClerc Y. North American clinical experience with the CarboMedics valve. Third International Clinical Symposium 1991; 6-19.
51 Logeais A. Mid-term results with CarboMedics valves. Proceedings Second International Clinical Symposium 1990; 13-20.
52 Macé M. Clinical experience. CarboMedics: Proceedings Second Clinical Symposium 1990; 3-11.
53 Rygg I, Aagaard J. Scandinavian clinical experience with the CarboMedics prosthetic heart valve. Third International Clinical Symposium 1991; 5-10.
54 Turinetto B. Initial experience with the CarboMedics prosthesis. Proceedings Second Clinical Symposium 1990; 101-4.
55 Roedler S, Moritz A, Schreiner W, Wolner E. Comparative experience with the CarboMedics and Duromedics valves. Third International Clinical Symposium 1991; 128-33.
56 CarboMedics. Summary of clinical investigation. Clinical Report 1991; 03: 1-4.
57 Dennis MS, Bamford JM, Sandercock PAG, Warlow CP. The incidence and prognosis of TIA in the community (1981-85). In: Cerebral Vascular Disease 6. Meyer J. (ed). Amsterdam: Elsevier; 1987: 35-41.
58 bOxfordshire Community Stroke Project. Incidence of stroke in Oxfordshire : First year’s experience of a community stroke register. Br Med J 1982; 287: 713-7.
59 Bamford J, Warlow Ch. Stroke and TIA in the general publication. In: Thrombosis, Embolism and Bleeding. Butchart EG, Bodnar E. (eds). London: ICR Publishers; 1992: 3-15.
60 Bodnar E. A critical assessment of thrombosis and embolism reporting methods. In: Thrombosis, Embolism and Bleeding. Butchart EG, Bodnar E. (eds). London: ICR Publishers; 1992: 476-84.
61 Grunkemeier G, Starr A. Alternatives to randomization in surgical studies. J Heart Valve Dis 1992; 01: 142-51.
62 Chen YT, Kan MN, Chen JS. Contributing factors to formation of left atrial spontaneous echo contrast in mitral valvular disease. J Ultrasound Med 1990; 09: 151-5.
63 Roberts WC, Morrow AG. Mechanisms of acute left atrial thrombosis after mitral valve replacement. Am J Cardiol 1966; 18: 497-503.
64 Caplan LR, D’Crux I, Hier DB, Reddy H, Shah S. Atrial size, atrial fibrillation and stroke. Ann Neurol 1986; 19: 158-61.
65 Daniel WG, Nellessen U, Schröder E. Left atrial spontaneous echo contrast in mitral valve disease: An indicator for an increased thromboembolic risk. JACC 1988; 11: 1204-11.
66 Daley R, Mattingsly TW, Holt CL, Bland EF, While PD. Systemic arterial embolism in rheumatic heart disease. Am Heart J 1951; 42: 566.
67 Coulshed N, Epstein EJ, McKendrick CS, Galloway RW, Walker E. Systemic embolism in mitral valve disease. Br Heart J 1970; 32: 36.
68 Abernathy WAS, Willis PW. Thromboembolic complications of rheumatic heart disease. Valvular Heart Disease 1973; 05: 132.
69 Acar J, Enriquez-Sarano M, Farah E, Kassab R, Tubian P, Rober V. Recurrent systemic embolic events with valve prosthesis. Eur Heart J 1984; 05 (Suppl D): 33-8.
70 Edmunds Jr LH. Thrombotic and bleeding complications of prosthetic heart valves. Ann Thorac Surg 1987; 44: 430-45.
71 Starr A, Grunkemeier GL. Recurrent embolism: Significance and management. In: Thrombosis, Embolism and Bleeding. Butchart EG, Bodnar E. (eds). London: ICR Publishers; 1992: 402-15.
72 Coulshed N, Epstein EJ, Walker E, Galloway RW. Systemic embolism in mitral stenosis. Br Heart J 1964; 21: 1393.